Table 5.
Expected lifetime results for high-risk patients
| Strategy | Lifetime costs (€) | Lifetime QALY | Net health benefita | Incremental analysis | Versus warfarin | ||||
|---|---|---|---|---|---|---|---|---|---|
| Incremental costs (€) | Incremental effects (QALY) | ICER (€/QALY) | Incremental costs (€) | Incremental effects (QALY) | ICER (€/QALY) | ||||
| Sequential dabigatran | 66,508 | 4.955 | 4.110 | −2,953 | 0.183 | −16,102 | |||
| Apixaban | 68,657 | 4.947 | 4.075 | 2,149 | −0.008 | Dominated | −804 | 0.175 | −4,585 |
| Warfarin | 69,461 | 4.771 | 3.889 | 2,953 | −0.183 | Dominated | |||
| Rivaroxaban | 71,849 | 4.888 | 3.975 | 7,402 | −0.064 | Dominated | 2,388 | 0.117 | 20,492 |
| Dabigatran 110 mg | 73,909 | 4.891 | 3.952 | 2,149 | −0.008 | Dominated | 4,448 | 0.119 | 37,250 |
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year
aIn QALYs; assuming a cost-effectiveness threshold of €79,000 per QALY